Progress in the genetics of primary biliary cirrhosis

Gideon M. Hirschfield, Pietro Invernizzi

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease that has a prevalence of 1 in 1000 women over the age of 40. Treatment is presently limited to ursodeoxycholic acid, a hydrophilic bile acid that has nonspecific, choleretic, effects in cholestatic liver disease. PBC has strong autoimmune features, including highly specific loss of tolerance to a ubiquitous mitochondrial antigen. Both environmental and genetic factors are considered important in the pathogenesis of disease. Prior to the advent of genome-wide association studies, only class II human leucocyte antigen (HLA) loci (HLA-DRB1*08,*11, and*13) had been reproducibly shown to associate with disease. Non-HLA loci were suggested for several genes (e.g., CTLA-4, MDR3), but often inconclusively replicated. With the application of genome-wide technology, HLA was confirmed as the strongest association and many other risk loci have been identified, with equivalent effect size to HLA, including IL12A, IL12RB2, STAT4, IRF5-TNPO3, 17q12.21, MMEL1, SPIB, and CTLA-4. These collectively support an important role for innate and adaptive immunity in development of disease. Further insights are predicted as studies with larger cohorts are assembled, and different approaches are taken to further discover common and uncommon gene variants associated with disease. Disease subphenotypes such as response to therapy, clinical progression, and symptoms remain additional areas for further dedicated studies, and in which different genetic risk factors may be relevant. Identification of risk loci associated with disease has the potential to aid development of rational, disease-specific, therapies in the future.

Original languageEnglish (US)
Pages (from-to)147-156
Number of pages10
JournalSeminars in Liver Disease
Volume31
Issue number2
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Biliary Liver Cirrhosis
HLA Antigens
Liver Diseases
Cholagogues and Choleretics
HLA-D Antigens
Ursodeoxycholic Acid
Genome-Wide Association Study
Adaptive Immunity
Bile Acids and Salts
Innate Immunity
Genes
Therapeutics
Genome
Technology
Antigens

Keywords

  • adaptive immunity
  • genome-wide association study
  • IL12
  • Innate immunity
  • IRF5
  • Primary biliary cirrhosis

ASJC Scopus subject areas

  • Hepatology

Cite this

Progress in the genetics of primary biliary cirrhosis. / Hirschfield, Gideon M.; Invernizzi, Pietro.

In: Seminars in Liver Disease, Vol. 31, No. 2, 2011, p. 147-156.

Research output: Contribution to journalArticle

Hirschfield, Gideon M. ; Invernizzi, Pietro. / Progress in the genetics of primary biliary cirrhosis. In: Seminars in Liver Disease. 2011 ; Vol. 31, No. 2. pp. 147-156.
@article{598176f455d44db1b5c2332573c687c7,
title = "Progress in the genetics of primary biliary cirrhosis",
abstract = "Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease that has a prevalence of 1 in 1000 women over the age of 40. Treatment is presently limited to ursodeoxycholic acid, a hydrophilic bile acid that has nonspecific, choleretic, effects in cholestatic liver disease. PBC has strong autoimmune features, including highly specific loss of tolerance to a ubiquitous mitochondrial antigen. Both environmental and genetic factors are considered important in the pathogenesis of disease. Prior to the advent of genome-wide association studies, only class II human leucocyte antigen (HLA) loci (HLA-DRB1*08,*11, and*13) had been reproducibly shown to associate with disease. Non-HLA loci were suggested for several genes (e.g., CTLA-4, MDR3), but often inconclusively replicated. With the application of genome-wide technology, HLA was confirmed as the strongest association and many other risk loci have been identified, with equivalent effect size to HLA, including IL12A, IL12RB2, STAT4, IRF5-TNPO3, 17q12.21, MMEL1, SPIB, and CTLA-4. These collectively support an important role for innate and adaptive immunity in development of disease. Further insights are predicted as studies with larger cohorts are assembled, and different approaches are taken to further discover common and uncommon gene variants associated with disease. Disease subphenotypes such as response to therapy, clinical progression, and symptoms remain additional areas for further dedicated studies, and in which different genetic risk factors may be relevant. Identification of risk loci associated with disease has the potential to aid development of rational, disease-specific, therapies in the future.",
keywords = "adaptive immunity, genome-wide association study, IL12, Innate immunity, IRF5, Primary biliary cirrhosis",
author = "Hirschfield, {Gideon M.} and Pietro Invernizzi",
year = "2011",
doi = "10.1055/s-0031-1276644",
language = "English (US)",
volume = "31",
pages = "147--156",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Progress in the genetics of primary biliary cirrhosis

AU - Hirschfield, Gideon M.

AU - Invernizzi, Pietro

PY - 2011

Y1 - 2011

N2 - Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease that has a prevalence of 1 in 1000 women over the age of 40. Treatment is presently limited to ursodeoxycholic acid, a hydrophilic bile acid that has nonspecific, choleretic, effects in cholestatic liver disease. PBC has strong autoimmune features, including highly specific loss of tolerance to a ubiquitous mitochondrial antigen. Both environmental and genetic factors are considered important in the pathogenesis of disease. Prior to the advent of genome-wide association studies, only class II human leucocyte antigen (HLA) loci (HLA-DRB1*08,*11, and*13) had been reproducibly shown to associate with disease. Non-HLA loci were suggested for several genes (e.g., CTLA-4, MDR3), but often inconclusively replicated. With the application of genome-wide technology, HLA was confirmed as the strongest association and many other risk loci have been identified, with equivalent effect size to HLA, including IL12A, IL12RB2, STAT4, IRF5-TNPO3, 17q12.21, MMEL1, SPIB, and CTLA-4. These collectively support an important role for innate and adaptive immunity in development of disease. Further insights are predicted as studies with larger cohorts are assembled, and different approaches are taken to further discover common and uncommon gene variants associated with disease. Disease subphenotypes such as response to therapy, clinical progression, and symptoms remain additional areas for further dedicated studies, and in which different genetic risk factors may be relevant. Identification of risk loci associated with disease has the potential to aid development of rational, disease-specific, therapies in the future.

AB - Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease that has a prevalence of 1 in 1000 women over the age of 40. Treatment is presently limited to ursodeoxycholic acid, a hydrophilic bile acid that has nonspecific, choleretic, effects in cholestatic liver disease. PBC has strong autoimmune features, including highly specific loss of tolerance to a ubiquitous mitochondrial antigen. Both environmental and genetic factors are considered important in the pathogenesis of disease. Prior to the advent of genome-wide association studies, only class II human leucocyte antigen (HLA) loci (HLA-DRB1*08,*11, and*13) had been reproducibly shown to associate with disease. Non-HLA loci were suggested for several genes (e.g., CTLA-4, MDR3), but often inconclusively replicated. With the application of genome-wide technology, HLA was confirmed as the strongest association and many other risk loci have been identified, with equivalent effect size to HLA, including IL12A, IL12RB2, STAT4, IRF5-TNPO3, 17q12.21, MMEL1, SPIB, and CTLA-4. These collectively support an important role for innate and adaptive immunity in development of disease. Further insights are predicted as studies with larger cohorts are assembled, and different approaches are taken to further discover common and uncommon gene variants associated with disease. Disease subphenotypes such as response to therapy, clinical progression, and symptoms remain additional areas for further dedicated studies, and in which different genetic risk factors may be relevant. Identification of risk loci associated with disease has the potential to aid development of rational, disease-specific, therapies in the future.

KW - adaptive immunity

KW - genome-wide association study

KW - IL12

KW - Innate immunity

KW - IRF5

KW - Primary biliary cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=79955634917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955634917&partnerID=8YFLogxK

U2 - 10.1055/s-0031-1276644

DO - 10.1055/s-0031-1276644

M3 - Article

C2 - 21538281

AN - SCOPUS:79955634917

VL - 31

SP - 147

EP - 156

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 2

ER -